Pascal Soriot

Type: Person

Name: Pascal Soriot

First reported May 21 2013 - Updated May 21 2013 - 1 reports

AstraZeneca Shakeup Of China Business Unit Steers Focus Away From Generics To Innovative Drugs

AstraZeneca will dissolve its Broad Market business unit in China by merging it with primary care and move away from attracting business for branded generics in tier-3 rural markets, putting flesh on new CEO Pascal Soriot’s plan to focus on innovatio ... [Published The Rose Sheet - May 21 2013]

Entities: Steers, AstraZeneca PLC, China, Drugs

First reported May 21 2013 - Updated May 21 2013 - 1 reports

AstraZeneca PLC

Astrazenecas Cambridge site list shortening

ASTRAZENECA is closing in on a site for its new $500m (327.7m) home in Cambridge, with a biomedical park just south of the English city the most likely site, say property industry sources.Moving research and global headquarters to Cambridge, with minimal ... [Published Equities.com - May 21 2013]

Entities: AstraZeneca PLC, MedImmune Inc, Pascal Soriot

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Michel Barnier

Golden Parachutes Face Clampdown in EU Law on Executive Pay

Golden parachute pay packages to departing company executives may face greater scrutiny from shareholders as part of European Union proposals to stem excessive awards.Michel Barnier, the European Union’s financial services chief, said he’ll seek to give ... [Published Bloomberg - May 16 2013]

Entities: Golden Parachute, Michel Barnier, European Union

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Unions fight Astra plans to move R&D base south

Union leaders will meet executives at AstraZeneca today to try to convince Britain's second-biggest drugmaker to reverse plans to close its R&D site in Cheshire and move almost 2,000 jobs. AstraZeneca wants to move its R&D hub from Alderley Park in Cheshire ... [Published The Independent - Apr 29 2013]

Entities: Research & Development, AstraZeneca PLC, Patent, Pascal Soriot

First reported Apr 28 2013 - Updated Apr 28 2013 - 1 reports

Primark Stores Ltd

Business week in review

In profit... Who likes a dire economy? Cut-price fashion chains for a start. Primark was buoyed by a 55 per cent profit hike to £238m in Tuesday's interim figures. But Britain is too small for George Weston, the boss of owner Associated British Foods. ... [Published The Independent - Apr 28 2013]

Entities: Primark Stores Ltd, George Weston (Associated British Foods PLC), António Horta-Osório, United Kingdom, Associated British Foods Plc

First reported Apr 26 2013 - Updated Apr 26 2013 - 1 reports

Astra profits plunge by third

Shareholders at AstraZeneca are getting restive. The company has long known that patent expiries, notably for anti-psychotic Seroquel, were going to eat into revenues, but it has so far failed to generate enough new products to replace them. In the event, ... [Published EIU - Apr 26 2013]

Entities: AstraZeneca PLC, Brilinta, Pascal Soriot, Seroquel

First reported Apr 25 2013 - Updated Apr 25 2013 - 13 reports

Astra profits plunge by third

AstraZeneca’s new boss faced a double-headache today as pre-tax profit tumbled by more than a third to $1.3 billion (£840 million) in the first quarter and a pay revolt loomed at his first AGM. Pascal Soriot, who joined from Roche last October, had little ... [Published The Independent - Apr 25 2013]

Entities: AstraZeneca PLC, Drugs, Restricted Shares, David Brennan, Brilinta

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

AstraZeneca Q1 sales tumble as generic losses bite deep

Sales of Brilinta - a new heart drug on which AstraZeneca is pinning high hopes - picked up modestly in the three months to end-March to $51 million (33 million pounds) from $38 million in the last quarter of 2012.The group reiterated its expectation ... [Published GlobalPost - Apr 25 2013]

Entities: AstraZeneca PLC, North Korea, Jane Merriman, Ben Hirschler, Drugs

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

US authorities investigate AstraZeneca's Macclesfield base

) it was helping authorities in America with an investigation into its plant in Macclesfield.The drugs group's base in the Cheshire town is its second largest manufacturing site and its European centre for packing.In an update to the London Stock Exchange ... [Published Insider Media Limited - Apr 25 2013]

Entities: AstraZeneca PLC, Subpoena, Manufacturing, Subpoena Duces Tecum

First reported Apr 25 2013 - Updated Apr 25 2013 - 2 reports

AstraZeneca hit by generic drugs and Crestor shortfall

Much of the damage was caused by loss of exclusivity on antipsychotic medicine Seroquel and heart drug Atacand in many markets.But the company's top-selling cholesterol fighter Crestor was also hit by generic competition in Canada, pricing pressure in ... [Published NewsRT.co.uk - Apr 25 2013]

Entities: Crestor, AstraZeneca PLC, Drugs

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Profits Dive 31% At AstraZeneca plc

AstraZeneca plc (LON: AZN) issues first-quarter results.The shares of AstraZeneca (LSE:$ AZN) (NYSE:$ AZN.US) dropped 1% to 3,353p during early London trade this morning after the FTSE 100 member reported first-quarter sales falling 13% to $6.4bn.AstraZeneca, ... [Published Motley Fool UK - Apr 25 2013]

Entities: AstraZeneca PLC, Brilinta, Pascal Soriot, Dividend

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

AstraZeneca First-Quarter Profit Fell 25% on Generics

AstraZeneca Plc (AZN), the U.K.’s second- biggest pharmaceutical company, said first-quarter profit fell 25 percent on increased generic competition for its best-selling drugs.Profit excluding some items declined to $2.32 billion, or $1.41 a share, from ... [Published Bloomberg - Apr 25 2013]

Entities: AstraZeneca PLC, Pascal Soriot, Drugs, Inflammation, treatments

More Content

sort by: Date \| Relevance
AstraZeneca Shakeup Of China Business Unit Stee... [Published The Rose Sheet - May 21 2013]
Astrazenecas Cambridge site list shortening [Published Equities.com - May 21 2013]
AstraZeneca closes in on site for new home in C... [Published NewsRT.co.uk - May 20 2013]
AstraZeneca closes in on site for new home in C... [Published London South East - May 20 2013]
Array BioPharma's CEO Presents at Bank of Ameri... [Published Seeking Alpha - May 16 2013]
Golden Parachutes Face Clampdown in EU Law on E... [Published Bloomberg - May 16 2013]
AstraZeneca revs up PhIII cancer plans as rival... [Published FierceBiotech - May 16 2013]
AstraZeneca accelerates cancer drug testing [Published Sharenet - May 16 2013]
AstraZeneca plc (ADR) (AZN): The Latest News [Published InsiderMonkey.com - May 15 2013]
Roche wins new targeted OK for Tarceva in EGFR-... [Published FiercePharma - May 15 2013]
AZ Giving Way to Early-Stage Biopharmas in Ches... [Published Genetic Engineering News - May 07 2013]
Unions fight Astra plans to move R&D base south [Published The Independent - Apr 29 2013]
Business week in review [Published The Independent - Apr 28 2013]
Astra profits plunge by third [Published EIU - Apr 26 2013]
AstraZeneca sales hit by generic drug competition [Published BDlive - Apr 25 2013]
Result of AGM [Published TrustNet - Apr 25 2013]
FTSE gains for third day after better than expe... [Published Equities.com - Apr 25 2013]
AstraZeneca's PhIII chief scouts for blockbuste... [Published FierceBiotech - Apr 25 2013]
Astra profits plunge by third [Published The Independent - Apr 25 2013]
Astra profits plunge by third [Published NewsRT.co.uk - Apr 25 2013]
AstraZeneca Q1 Earnings: Profit Fell 25 Percent... [Published Value Walk - Apr 25 2013]
AstraZeneca profits plunge by third [Published London Evening Standard - Apr 25 2013]
Earnings battered but AZ optimistic for future ... [Published Pharma Times - Apr 25 2013]
AstraZeneca's net falls by 53% to $828 million ... [Published PharmaBiz - Apr 25 2013]
AstraZeneca earnings per share declined 31 perc... [Published Philadelphia Inquirer - Apr 25 2013]
AstraZeneca hit by generic drugs and Crestor sh... [Published NewsRT.co.uk - Apr 25 2013]
AstraZeneca First-Quarter Profit Down 36% on Ma... [Published International Business Times UK - Apr 25 2013]
AstraZeneca sales drop 13% in first quarter [Published Delaware Online - Apr 25 2013]
AstraZeneca profits decline after after losing ... [Published MyNewsDesk - Apr 25 2013]
Mixed Results for Drug Companies [Published Capital.gr - Apr 25 2013]

sort by: Date \| Relevance
Deals Of The Week Wonders Whether Heated Compet... [Published The IN VIVO Blog - Apr 05 2013] Could a bidding war for Brazil’s privately held Ache Laboratorios do for Latin America what Abbott Laboratories Inc.’s gargantuan purchase of part of India’s Piramal Healthcare did for biopharma M&A in India?Call it the “Piramal effect,” if you will. ...
Here’s A Blow To AstraZeneca’s Drug Portfolio [Published Wall St. Cheat Sheet - Apr 02 2013] AstraZeneca ( NYSE:AZN ) has traveled a bumpy road in recent months after facing sharp declines in revenue as patents on top-selling drugs — including the cholesterol treatment Crestor and its antipsychotic medicine Seroquel — expire. And the pharmaceutical ...
Will AstraZeneca’s Patent Setback Put Off These... [Published Wall St. Cheat Sheet - Apr 02 2013] AstraZeneca ( NYSE:AZN ) suffered a fresh patent setback with a U.S. court decision that a patent protecting its Pulmicort Repsules asthma treatment is invalid, which will allow a generic copy from Actavis, Reuters reported. This ruling comes as AstraZeneca ...
Court Rules AstraZeneca's U.S. Pulmicort Patent... [Published PharmaGossip - Apr 02 2013] A court has ruled that a patent protecting AstraZeneca PLC's (AZN.LN) Pulmicort Respules asthma drug in the U.S. is invalid, the company said Tuesday, dealing a blow to the company's dwindling drugs portfolio and allowing U.S. generic drugmaker Actavis ...
FT column: Killing projects is the hardest inno... [Published FT.com - John Gapper's Business Blog - Apr 01 2013] Pascal Soriot, AstraZeneca’s new chief executive, has just laid out a new strategy to “focus, accelerate and transform” the pharmaceutical company. Mark Thompson, newly arrived at the helm of The New York Times Company, has promised to “concentrate [the ...

sort by: Date \| Relevance
AstraZeneca Outlines Strategy to Return to Grow... [Published Business Wire Health News - Mar 21 2013]
ASTRAZENECA OUTLINES STRATEGY TO RETURN TO GROW... [Published GlobeNewswire: Acquisitions News - Mar 21 2013]
ASTRAZENECA OUTLINES STRATEGY TO RETURN TO GROW... [Published CisionWire - English - Mar 21 2013]